Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H30N2O6 |
| Molecular Weight | 466.5262 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C2COC(=O)C2=CC=C1[C@@H](O)CN3CCN(C[C@H](O)C4=CC=C5C(=O)OCC5=C4C)CC3
InChI
InChIKey=OCKGFTQIICXDQW-ZEQRLZLVSA-N
InChI=1S/C26H30N2O6/c1-15-17(3-5-19-21(15)13-33-25(19)31)23(29)11-27-7-9-28(10-8-27)12-24(30)18-4-6-20-22(16(18)2)14-34-26(20)32/h3-6,23-24,29-30H,7-14H2,1-2H3/t23-,24-/m0/s1
MK-7145 is a piperazine derivative patented by Merck Sharp & Dohme Corporation as the renal outer medullary potassium channel inhibitor useful for the treatment of hypertension and heart failure. In preclinical studies, MK-7145 shows selectivity against other cardiac ion channels such as Cav1.2, Nav1.5, and Kir2.1, Kir2.3, Kir4.1, or Kir7.1. In 2011 MK-7145 was studied in phase I clinical trials but no further development reports were published.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M371870BYL
Created by
admin on Sat Dec 16 03:08:12 GMT 2023 , Edited by admin on Sat Dec 16 03:08:12 GMT 2023
|
PRIMARY | |||
|
59568713
Created by
admin on Sat Dec 16 03:08:12 GMT 2023 , Edited by admin on Sat Dec 16 03:08:12 GMT 2023
|
PRIMARY | |||
|
DB11968
Created by
admin on Sat Dec 16 03:08:12 GMT 2023 , Edited by admin on Sat Dec 16 03:08:12 GMT 2023
|
PRIMARY | |||
|
1255204-84-2
Created by
admin on Sat Dec 16 03:08:12 GMT 2023 , Edited by admin on Sat Dec 16 03:08:12 GMT 2023
|
PRIMARY | |||
|
100000175783
Created by
admin on Sat Dec 16 03:08:12 GMT 2023 , Edited by admin on Sat Dec 16 03:08:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
